Inventiva to participate at several investor conferences in September 2020
Daix (France), September 9, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies for the treatment of non-alcoholic
steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need,
today announced that its management team will participate to five investor conferences in September 2020.